TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04211909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet orally once daily.
Study: NCT01917162

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lens
Description: Soft contact lens CE-marked for daily disposable wear.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lens
Description: Soft contact lens CE-marked for daily disposable wear.

Intervention type: DEVICE
Group type: OTHER
Intervention: UltraFilcon B contact lens
Description: Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: UltraFilcon B contact lens
Description: Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.
Study: NCT00971152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: menotropins for injection
Description: comparison of different dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menotropins for injection
Description: comparison of different dosages

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urofollitropin for injection
Description: comparison of different dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urofollitropin for injection
Description: comparison of different dosages
Study: NCT03348228

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycitrate (HCA)
Description: Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxycitrate (HCA)
Description: Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
Study: NCT00635297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous vertebroplasty
Description: PMMA injection 3-10 milliliter in each treated vertebrae

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Description: PMMA injection 3-10 milliliter in each treated vertebrae
Study: NCT02180776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Summit 456 TLSO
Description: Thoracolumbarsacral orthosis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Summit 456 TLSO
Description: Thoracolumbarsacral orthosis
Study: NCT02888119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRISMA 3T MRI scanner (Siemens Medical Solutions)
Description: A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRISMA 3T MRI scanner (Siemens Medical Solutions)
Description: A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRISMA 3T MRI scanner (Siemens Medical Solutions)
Description: A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
Study: NCT00031278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin®
Description: Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
Study: NCT00831480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
Study: NCT00201188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Status Reports
Description: Interpreted Analysis of Peak-Flow Monitoring Trends
Study: NCT03565497

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wellness Education Control Condition
Description: As per arm of the same name

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: As per arm of the same name

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training Plus IE
Description: As per arm of the same name
Study: NCT01075685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive online programme to reduce alcohol consumption
Description: The programme includes several steps:~* personalized feedback on alcohol consumption and related risks~* reviewing motivations and fears regarding drinking reduction~* analyse of drinking habits~* reduction goal setting~* follow-up tools (alcohol diary, craving scales, well-being scales)~* a final screen allowing participants to monitor their progress through graphs and automatically adapted comments.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimum information
Description: This intervention includes:~* information about hazardous drinking~* an alcohol diary
Study: NCT01255683

Intervention type: DRUG
Intervention: oral corticosteroid taper
Description: This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
Study: NCT01802996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Isoglycyrrhizinate Injection
Description: 200mg IV on day 1-5
Study: NCT01125696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/lamivudine/lopinavir-ritonavir
Description: Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine/lamivudine/lopinavir-ritonavir
Description: Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4\<350
Study: NCT02592096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% Pazufloxacin Mesilate Ear Drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% Pazufloxacin Mesilate Ear Drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Pazufloxacin Mesilate Ear Drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazufloxacin mesilate injection
Study: NCT04565639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered Hand Orthosis
Description: A prototype powered hand orthosis system designed to improve grip strength and improve ability to perform tasks of daily living.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered Hand Orthosis
Description: A prototype powered hand orthosis system designed to improve grip strength and improve ability to perform tasks of daily living.
Study: NCT03444636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine/Fentanyl
Description: Ropivacaine 0.2% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine/Fentanyl
Description: Bupivacaine 0.125% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
Study: NCT00380367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
Study: NCT04301505

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 1
Description: Checklist will be delivered at the beginning of the study. The educational intervention program will consist of a checklist that provides family physicians with COPD management for the elderly.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 2
Description: The same checklist will be delivered at the beginning of the study and repeated after 6 months.
Study: NCT02906176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend (voriconazole) intravenous infusion
Description: Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend (voriconazole) intravenous infusion
Description: Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend (voriconazole) tablet
Description: Vfend (voriconazole) 200 mg tablet once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vfend (voriconazole) tablet
Description: Vfend (voriconazole) 200 mg tablet once
Study: NCT02541396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine
Description: 35 or 70 mg ketamine in a sublingual wafer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine
Description: 35 or 70 mg ketamine in a sublingual wafer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine
Description: 35 or 70 mg ketamine in a sublingual wafer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine
Description: 35 or 70 mg ketamine in a sublingual wafer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wafermine
Description: 35 or 70 mg ketamine in a sublingual wafer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5 mg oxycodone capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg oxycodone capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg oxycodone capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule or placebo wafer
Study: NCT02897856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buccal midazolam
Description: Study subject will receive Buccal midazolam, Intramuscular placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular midazolam
Description: Study subject will receive Intramuscular midazolam,Buccal placebo
Study: NCT04223219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate \>20% of baseline or hypertension: increase of blood pressure \>20% of baseline).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl, Propofol
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxugen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, Ketamine, Magnesium sulfate
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive infusions of dexmedetomidine 0.2 µg/kg/h, ketamine 2 µg/kg/min, and magnesium sulfate 5 mg/kg/h.~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.
Study: NCT01526759

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LM pectin (10%)
Description: 15 days 1 daily consumption of a drink with 10g pectin added

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: gelatin
Description: 15 days 1 daily consumption of a drink with 10g gelatin added
Study: NCT01092117

Intervention type: DEVICE
Group type: OTHER
Intervention: Ovation™ Abdominal Stent Graft System
Description: Implant of Ovation™ Abdominal Stent Graft System
Study: NCT02138448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Preventive Health Record
Description: The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
Study: NCT04551534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL201
Description: Oral dose(s)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose(s)
Study: NCT03358524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 UNT
Description: Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: sugar capsule manufactured to mimic vitamin E capsule once per day
Study: NCT01623050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinuSys Dilation System
Description: Sinuplasty
Study: NCT02238080

Intervention type: DRUG
Intervention: Methoxy Polyethylene Glycol-Epoetin Beta
Description: Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
Study: NCT06370403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooling of the head and neck
Description: Cooling of the head and neck at 18°C next to the head and neck skin in multiple sclerosis and healthy subjects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heating of the head and neck
Description: Heating of the head and neck at 43 ± 1°C next to the head and neck skin in multiple sclerosis
Study: NCT01694407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir (TFV) Alone Vaginal Tablet
Description: vaginal tablet containing 40 mg of TFV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine (FTC) Alone Vaginal Tablet
Description: Vaginal Tablet containing 40 mg of TFV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TFV and FTC Combined Vaginal Tablet
Description: vaginal tablet with 40 mg TFV and 40 mg FTC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Tablet
Description: Vaginal Tablet containing no drug
Study: NCT00393861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Oxaliplatin
Description: Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
Study: NCT00332722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical facet joint nerve blocks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical facet joint nerve blocks
Study: NCT00459186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Infusion once per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg by mouth twice daily
Study: NCT02516852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg production
Description: Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
Study: NCT02170415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protective analgesia
Description: Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.~For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain education
Description: Participant will receive a pain education leaflet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological support
Description: Participants demonstrating psychological morbidity will be offered psychological support prior to surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block/local anaesthetic infiltration
Description: Patients on the intervention limb will be encouraged to have a paravertebral block if not contraindicated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily visits from pain team whilst in hospital
Study: NCT03415542

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Promotion
Description: Evidence-based techniques (goal-setting, reduced barriers) for increasing exercise behavior
Study: NCT02352155

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine injection or heater probe or hemoclips
Description: Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation only
Description: Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
Study: NCT02501395

Intervention type: OTHER
Intervention: No intervention, observational

Intervention type: OTHER
Intervention: No intervention, observational
Study: NCT00540332

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Description: 120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
Study: NCT04101942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Description: The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours.
Study: NCT00685568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Orally, twice daily for 3 months
Study: NCT02459834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allulose
Description: A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate \& Lyle.
Study: NCT04462588

Intervention type: DRUG
Intervention: Cipro 400 MG in 200 ML Injection
Description: medical tratment group

Intervention type: DRUG
Intervention: Flagyl I.V. RTU
Description: medical tratment group

Intervention type: PROCEDURE
Intervention: appendectomy (open or laparascopic)
Description: appendectomy (open or laparascopic)